News in brief - May 2013

Other new launches, licence changes and prescribing updates relevant to general practice.

The integrase inhibitor raltegravir (Isentress) provides a new treatment option for paediatric patients with HIV
The integrase inhibitor raltegravir (Isentress) provides a new treatment option for paediatric patients with HIV
  • A generic equivalent of Malarone (atovaquone/proguanil) has been launched for the prophylaxis and treatment of acute uncomplicated P. falciparum malaria.
  • The antidiabetic combination tablet Komboglyze (metformin/saxagliptin) is now indicated for use in combination with a sulfonylurea when a sulfonylurea plus metformin is inadequate.
  • A licensed oral suspension of clobazam, Tapclob, has been launched for use as an adjunct in epilepsy.
  • Isentress (raltegravir) is now available as chewable tablets to treat HIV-1 infection in children from the age of 2 years.
  • The cannabis-based MS spasticity treatment Sativex has been reclassified as a Schedule 4 CD, meaning that it can now be prescribed as a POM without any restrictions.

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.